Compare ADMA Biologics Inc (ADMA) vs Tempus AI (TEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Tempus AI — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Tempus AI trades at $56.75 (market cap $10.79B). The key difference: Tempus AI is far larger — about 5.1× ADMA Biologics Inc's market cap, and Tempus AI is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TEM | |
|---|---|---|
Market Cap | $2.13B | $10.79B |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $103.25 |
52-Week Low | $7.60 | $42.37 |
Enterprise Value | $2.20B | $11.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Tempus AI (TEM) trades at $60.70, up 0.71% with a bullish technical signal. The stock shows strong analyst support with 8 buy ratings and a $63.50 consensus target, though fundamentals reveal challenges with a -22.2% net margin and -$245M net loss for 2025. Recent FDA approvals and AI platform expansions drive positive sentiment, while cash flow remains dependent on financing activities.
Outlook remains cautiously optimistic given TEM's unique AI healthcare data platform and expanding partnerships, but investors face significant execution risks amid persistent losses. The stock's 7.85 P/S ratio reflects growth expectations, yet profitability concerns and high cash burn require careful monitoring for sustainable turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
